NHS Branded Medicines Tranche Framework for London and South of England
Buyer: NHS England
- Published
- 20 August 2024
- Estimated value
- £39
- Place of performance
- UK
- Procedure
- Open procedure
- Notice number
- 026491-2024
- Reference
- ocds-h6vhtk-0445bc
- Official source
- Official source
CPV codes
- 33600000Pharmaceutical products
Description
NHS Branded Medicines Tranche Framework for London and South of England - 1 September 2024 Offer reference number: CM/PHR/22/5689 CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South of England Tranche A. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South of England Tranche B. Period of framework: 1 September 2024 to 31 August 2026 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/03 - NHS Framework for the supply of Omalizumab and Diroximel Fumarate for the Midlands & East and North of England. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.
Lots (3)
| Lot | Description | CPV code | Amount |
|---|---|---|---|
| 1 | CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South - Lot 1 | 33600000 Pharmaceutical products | — |
| 2 | CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South - Lot 2 | 33600000 Pharmaceutical products | — |
| 3 | CM/PHR/22/5689/03 - Omalizumab and Diroximel Fumarate for MAE & NOFE - Lot 3 | 33600000 Pharmaceutical products | — |
Awards
| Awarded to | Amount | Date |
|---|---|---|
| Biogen | — | — |
| Eli Lilly and Company Ltd | — | — |
| Aventis Pharma t/a Sanofi | — | — |
| ACCORD-UK LTD | — | — |
| Manx Healthcare Ltd | — | — |
| Chugai Pharma UK Ltd | — | — |
| Dr.Reddy's Laboratories (UK) Limited | — | — |
| Gedeon Richter UK Ltd | — | — |
| CELLTRION HEALTHCARE UNITED KINGDOM LIMITED | — | — |
| Teva UK Limited | — | — |
Official publications
- FTS · 026491-2024 · 20 August 2024
Other tenders from NHS England
- Enhanced Mental Health Pathway
- Enhanced Mental Health Pathway
- NHS Vaccination and Immunisation Services
- NHS Vaccination and Immunisation Services
- Fertility service for preservation and use of reproductive tissue for service users who cannot store mature eggs/sperm who are at high/very…
- Integrated Healthcare Services at HMP Welland Oaks
- Tier 4 Lead Provider for CAMHS
- Onasemnogene Abeparvovec Intravenous (Zolgensma®) Service & Onasemnogene Abeparvovec Intrathecal (OAV101 IT) Service
- Black Country Covid-19 Targeted Outreach Intervention: Mobile vaccination provision
- Covid Vaccinations to Nottinghamshire Housebound Patients
Frequently asked questions
- What is the estimated value of this tender?
- The estimated value published by the buyer is £39.
- Who is the buyer of this tender?
- The contracting authority is NHS England (United Kingdom).
- How can I bid for public tenders in the United Kingdom?
- Bids are submitted through the official public procurement portal in the United Kingdom. El Vínculo helps you find tenders and analyse their documents; submission always happens at the official source.
Create a free account and receive new public tenders published in the United Kingdom that match your business, every day.